BR100 Increased By (0.34%)
BR30 Increased By (0.77%)
KSE100 Increased By (0.26%)
KSE30 Increased By (0.25%)
BECO 5.73 Increased By ▲ 0.34 (6.31%)
BML 57.30 Decreased By ▼ -0.16 (-0.28%)
BOP 36.77 Increased By ▲ 0.46 (1.27%)
CNERGY 8.39 Increased By ▲ 0.18 (2.19%)
DCL 12.04 Increased By ▲ 0.21 (1.78%)
FCCL 58.61 Decreased By ▼ -0.67 (-1.13%)
FCSC 5.01 No Change ▼ 0.00 (0%)
FFL 17.94 Increased By ▲ 0.09 (0.5%)
FNEL 1.26 No Change ▼ 0.00 (0%)
HUMNL 11.42 Decreased By ▼ -0.08 (-0.7%)
KEL 8.29 Decreased By ▼ -0.04 (-0.48%)
KOSM 6.62 Decreased By ▼ -0.01 (-0.15%)
MLCF 108.29 Increased By ▲ 0.86 (0.8%)
NBP 206.04 Increased By ▲ 1.03 (0.5%)
PACE 11.17 Increased By ▲ 0.07 (0.63%)
PAEL 45.35 Decreased By ▼ -0.07 (-0.15%)
PIAHCLA 30.77 Decreased By ▼ -0.99 (-3.12%)
PIBTL 19.06 Increased By ▲ 0.21 (1.11%)
PPL 245.95 Increased By ▲ 2.21 (0.91%)
PRL 36.08 Decreased By ▼ -0.16 (-0.44%)
PTC 72.36 Increased By ▲ 0.29 (0.4%)
SEARL 96.67 Increased By ▲ 2.09 (2.21%)
SSGC 31.67 Decreased By ▼ -0.18 (-0.57%)
TELE 9.27 Increased By ▲ 0.25 (2.77%)
THCCL 67.81 Decreased By ▼ -0.66 (-0.96%)
TPLP 11.23 Increased By ▲ 0.51 (4.76%)
TREET 25.89 No Change ▼ 0.00 (0%)
TRG 67.84 Increased By ▲ 3.53 (5.49%)
WAVES 10.98 Increased By ▲ 0.07 (0.64%)
WTL 1.28 Decreased By ▼ -0.01 (-0.78%)
Business & Finance

Pfizer partner BioNTech sees no role for its vaccine in UK challenge trial

  • Britain is planning to host so-called "challenge trials", the Financial Times cited people involved in the project as saying.
Published September 24, 2020 Updated September 24, 2020 03:18pm
By

FRANKFURT: Pfizer's German development partner BioNTech on Thursday joined other leading COVID-19 vaccine developers in ruling out participation in British plans to test experimental inoculations by deliberately infecting trial volunteers.

"BioNTech's vaccine candidate is not part of this study," a spokeswoman said.

Britain is planning to host so-called "challenge trials", the Financial Times cited people involved in the project as saying.

Britain said it was working with partners on the potential for human challenge trials without commenting on a specific plan.

AstraZeneca and Sanofi both have said their vaccine candidates were not involved in the programme.

Comments

Comments are closed for this article.